The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InING Groep NV significantly increased its investment in healthcare giant Johnson & Johnson (JNJ) during the third quarter, acquiring an additional 266,299 shares. This strategic move brings ING's total holdings in JNJ to 959,228 shares, valued at an impressive $177.86 million. The increased stake signals strong institutional confidence in Johnson & Johnson's market position and future prospects. Analysts currently maintain a "Moderate Buy" consensus rating for JNJ, with a target price set at $233.73, further reinforcing positive sentiment. Moreover, Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, payable on March 10th. This substantial institutional investment, combined with positive analyst outlooks and consistent dividend payouts, underscores a bullish sentiment surrounding JNJ stock.